|Application / Reactivity||Primate||Human|
|Enzyme Immunoassay (EIA)||1 Antibodies||2 Antibodies|
|Flow Cytometry (FACS)||19 Antibodies||313 Antibodies|
|Immunohistochemistry (IHC)||12 Antibodies||90 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||13 Antibodies|
|Immunoprecipitation (IP)||4 Antibodies|
|Western Blotting (WB)||1 Antibodies|
|Cytometry by Time of Flight (CyTOF)||5 Antibodies|
|Functional Studies (Func)||3 Antibodies|
|Immunochromatography (IC)||1 Antibodies|
|Immunocytochemistry (ICC)||12 Antibodies|
|Immunofluorescence (IF)||55 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||1 Antibodies|
|Immunohistochemistry (Acetone-fixed) (IHC (af))||3 Antibodies|
|Antigen||Complement Decay-Accelerating Factor (CD55) Antibodies|
|Reactivity||Human, Primate Alternatives|
|Conjugate||This CD55 antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-CD55 AntibodyTarget Details CD55 Application Details Handling Images
Species reactivity (expected):Primates.
Species reactivity (tested):Human.
|Characteristics||Synonyms: Complement decay-accelerating factor|
|Purification||Size Exclusion Chromatography.|
|Immunogen||HPB-ALL human T cell line.|
Target Details CD55Product Details anti-CD55 Antibody Application Details Handling Images back to top
|Alternative Name||CD55 / DAF (CD55 Antibody Abstract)|
|Background||Avoidance by host tissues of attack by autologous complement proteins is dependent in part on the activities of membrane regulatory factors. One molecule involved in this control is a 70 kD glycoprotein termed decay-accelerating factor (DAF), or CD55. Interruption by CD55 of the complement sequence at an early step in activation effectively halts progression of the cascade and prevents consequent cell injury. In man, CD55 is expressed on the plasma membrane of all cell types that are in intimate contact with plasma complement proteins. This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. CD55 also acts as the receptor for echovirus 7 and related viruses(echoviruses 13, 21, 29 and 33). It is attached to the membrane by a GPI-anchor.Synonyms: Complement decay-accelerating factor|
Application DetailsProduct Details anti-CD55 Antibody Target Details CD55 Handling Images back to top
Flow Cytometry. Immunoprecipitation. Immunohistochemistry on Paraffin Sections: 10 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-CD55 Antibody Target Details CD55 Application Details Images back to top
|Buffer||PBS ~ pH 7.4 containing 15 mM Sodium Azide as preservative.|
|Precaution of Use||This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage||4 °C/-20 °C|
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.
|Expiry Date||12 months|
ImagesProduct Details anti-CD55 Antibody Target Details CD55 Application Details Handling back to top